Marketing: Page 7
-
Amazon will see you now: reading between the lines of the One Medical acquisition
The deal’s near-term effects might not be large, but Amazon’s acquisition still threaten’s One Medical’s primary care competitors and others seeking a greater slice of the market, experts said.
By Rebecca Pifer • July 25, 2022 -
Sean Gallup via Getty Images
EU speeds approval of monkeypox vaccine as WHO declares public health emergency
Vaccine maker Bavarian Nordic said it is meeting demand for its shot with production capacity of 30 million doses a year.
By Christopher Newman • July 25, 2022 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Depositphotos_40325215_originalamazon
Amazon to buy One Medical for $3.9B
The all-cash deal for the San Francisco-based company follows months of speculation about a potential acquisition, but Amazon as the buyer comes as a surprise.
By Rebecca Pifer • July 21, 2022 -
Jessica McGowan/Getty Images via Getty Images
CDC backs Novavax's protein-based vaccine for COVID-19
Health officials argue a new type of shot could help to persuade unvaccinated people, although some surveys suggest that might not be the case.
By Delilah Alvarado • July 20, 2022 -
piranka via Getty Images
Ultragenyx sells rare disease drug royalties to Canadian pension fund
In exchange for $500 million, the fund, called OMERS, will get a 30% royalty on future sales of Ultragenyx’s drug Crysvita in the U.S. and Canada, where it’s approved to treat two rare conditions.
By Jacob Bell • July 15, 2022 -
yodiyim via Getty Images
Royalty Pharma buys rights to top-selling GSK drug in pair of deals
The prolific biopharma dealmaker is paying Theravance $1.1 billion and Innoviva $282 million to acquire rights to royalties on GSK’s asthma and COPD drug Trelegy Ellipta.
By Kristin Jensen • July 14, 2022 -
Getty / Edited by BioPharma Dive
BioMarin's hemophilia gene therapy recommended for approval in Europe
The decision brings what could be the first approved hemophilia gene therapy, Roctavian, closer to market, after a series of regulatory setbacks that have delayed its arrival.
By Jacob Bell • June 24, 2022 -
koto_feja via Getty Images
Amylyx's ALS drug gets approved in Canada
The Massachusetts-based biotech is awaiting a decision in the U.S., where the FDA recently extended its review after agency advisers narrowly voted against the treatment.
By Jacob Bell • June 13, 2022 -
Permission granted by Fizkes, OM1
Sponsored by OM1Real-world data: A health equity lens for research
Arising from the circumstances in which people grow, live, work and age, and the systems put in place to deal with illness, these health inequities are avoidable.
By Jessica Paulus, ScD, Senior Director, Epidemiology, OM1 • June 13, 2022 -
Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
FTC to investigate CVS Caremark, others in probe of PBM business practices
The decision to launch an inquiry reversed a vote earlier this year, when FTC commissioners had deadlocked over whether to look into the drug pricing middlemen.
By Rebecca Pifer • June 7, 2022 -
Amarin
Amarin turns to job cuts as generics challenge its heart pill
Facing greater competition and declining sales in the U.S., the drugmaker is laying off about 40% of its workforce as part of an effort to save $100 million over the next year.
By Jacob Bell • June 6, 2022 -
Regeneron buys control of cancer drug Libtayo from Sanofi
The biotech, which has been partnered with Sanofi for years, will pay $900 million upfront to gain sole control of the cancer immunotherapy.
By Jonathan Gardner • Updated June 2, 2022 -
Maddie Meyer via Getty Images
Moderna vaccine sales surpass expectations as company looks to fall boosters
The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S. might shift from the federal government to private payers.
By Ned Pagliarulo • May 4, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers wins FDA approval for first drug to treat inherited heart condition
Bristol Myers paid $13 billion to acquire the drug's maker, MyoKardia, and expects it to become a blockbuster. But a tricky dosing regimen, as well as safety concerns, could challenge the pharmaceutical giant's lofty forecast.
By Jonathan Gardner • April 28, 2022 -
Permission granted by Biogen
Biogen pulls European application for Aduhelm in another setback for the Alzheimer's drug
In a letter to regulators, Biogen said it chose to withdraw its approval filing after discussions with the EMA, which previously found the data supporting Aduhelm to be lacking.
By Jacob Bell , Ned Pagliarulo • April 22, 2022 -
bpperry via Getty Images
DOJ cracks down on 'largest and most wide-ranging' COVID-19 fraud
Defendants, including doctors, medical business executives and fake vaccination card manufacturers, caused nearly $150 million in false billings to federal programs, the DOJ said.
By Rebecca Pifer • April 21, 2022 -
Permission granted by GoodRx
Sponsored by GoodRxInflation is forcing prioritization of healthcare spending — are you ready?
Inflation means your customers' money doesn't travel as far as it did a few weeks ago.
April 18, 2022 -
Permission granted by Akili Interactive
Deep DiveCan digital therapeutics be profitable?
Licensing deals with pharmaceutical companies were an early strategy for digital health companies, but not all of them have lasted.
By Elise Reuter • April 11, 2022 -
adobe.com/Tierney
Sponsored by Acceleration PointThe power of alerts
As medical affairs continues to invest in systems and data, it can quickly become overwhelming to keep up with it all.
April 11, 2022 -
Getty Images
Medicare finalizes policy limiting coverage of Biogen Alzheimer's drug
Biogen said it is considering its options following CMS' decision, which restricts reimbursement of Aduhelm to patients enrolled in a randomized clinical trial.
By Jonathan Gardner • Updated April 7, 2022 -
Fizkes/Shutterstock.com
Sponsored by OM1A new approach for post-marketing safety studies
The large quantity of digitized healthcare data in the U.S. presents an enormous opportunity to shift dramatically how post-marketing safety studies can and should be conducted.
By Stefan Weiss, MD, MHSc, MBA, Managing Director of Dermatology, OM1 • April 4, 2022 -
AbbVie
Deep Dive // Patent thicketsTwo decades and $200 billion: AbbVie’s Humira monopoly nears its end
The first biosimilar copy of Humira is set to arrive in the U.S. next week, testing both AbbVie and the market potential for knockoff biologic drugs.
By Jonathan Gardner • Updated Jan. 27, 2023 -
Permission granted by Akili Interactive
Akili, with plans to go public, prepares to ramp up marketing of video game treatment
"We've proven that foundation and now it's time to run and scale," said CEO Eddie Martucci. The company is going public through a $1 billion SPAC, rather than a traditional IPO.
By Elise Reuter • March 10, 2022 -
AbbVie
AbbVie holds off another Humira challenger with Alvotech deal
A settlement will allow the Iceland-based drugmaker to launch its Humira copycat, currently under FDA review, in the U.S. beginning next July.
By Ned Pagliarulo • March 9, 2022 -
Novo Nordisk
Novo sees fast growth ahead of obesity drugs despite production hurdles
The Danish drugmaker aims to triple sales of its weight loss treatments Wegovy and Saxenda by 2025. But first, Novo needs to resolve manufacturing constraints that have slowed the former drug's launch.
By Ned Pagliarulo • March 4, 2022
Previous
